Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities.
about
Kinase Signaling in Apoptosis Induced by Saturated Fatty Acids in Pancreatic β-CellsDC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-Cells dysfunction in db/db miceT cells cooperate with palmitic acid in induction of beta cell apoptosis.Group VIA phospholipase A2 mitigates palmitate-induced β-cell mitochondrial injury and apoptosisMetformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO SystemChronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activity.Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes.Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist PioglitazoneNeuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells.Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis.Activation of survival and apoptotic signaling pathways in lymphocytes exposed to palmitic acid.Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide.
P2860
Q28079845-857E473D-4272-481D-9CAC-2911E8F4ABD8Q28533802-D32E0AAE-6D5B-4484-BB78-E645977BBC82Q33451028-EBD1100B-C4E1-4A7D-BF6B-20CB2CC01C56Q33619491-F118385D-EC7D-4F99-B9DD-C9BCBD929DEEQ34679569-9D0F5B74-9FBB-48A2-8A46-A5DEDC037578Q34787903-5A32ECFF-2AF4-4A1E-81DD-511EB0A3893AQ36301880-0CC1EE1E-7FBA-4D84-AE63-54BC8B054293Q36686786-87E24B0D-920A-42E7-8F3B-C33A8C385325Q37256315-EB3C4BFA-6A79-49D3-B6A0-33030D5E5A5CQ38937256-062F0A76-08BD-4381-AE8F-60F6E0B9DB83Q39406788-68554F20-A655-4C98-8ACF-7A71235F3862Q39570701-DDC9F0CB-7576-416E-B9DC-DBF7C6000821Q43224961-3C57406C-4BE0-481D-B8EE-D6B2F575118E
P2860
Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@en
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@nl
type
label
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@en
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@nl
prefLabel
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@en
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@nl
P1476
Rosiglitazone counteracts palm ...... hase and caspase 3 activities.
@en
P2093
I Lundquist
S Meidute Abaraviciene
P2888
P304
P356
10.1007/S00018-008-8100-8
P577
2008-07-01T00:00:00Z